184 related articles for article (PubMed ID: 31778618)
1. Health Care Utilization and Economic Burdens of Hemochromatosis in the United States: A Population-Based Claims Study.
Elsaid MI; John T; Li Y; Koduru S; Ali SZ; Catalano C; Narayanan N; Rustgi VK
J Manag Care Spec Pharm; 2019 Dec; 25(12):1377-1386. PubMed ID: 31778618
[TBL] [Abstract][Full Text] [Related]
2. Wilson's Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States.
Rustgi VK; Gupta K; Tait C; Bhurwal A; Kabaria S; Catalano C; Li Y; Minacapelli CD
Hepatol Commun; 2022 Feb; 6(2):389-398. PubMed ID: 34559472
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States.
Elsaid MI; Li Y; Catalano C; Minacapelli CD; Gupta K; Rustgi VK
Pharmacoecon Open; 2021 Mar; 5(1):89-100. PubMed ID: 32897528
[TBL] [Abstract][Full Text] [Related]
5. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
[TBL] [Abstract][Full Text] [Related]
8. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
10. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Illness in Adult Patients with Nocturia.
Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
[TBL] [Abstract][Full Text] [Related]
12. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
13. Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
Brummett CM; England C; Evans-Shields J; Kong AM; Lew CR; Henriques C; Zimmerman NM; Pawasauskas J; Oderda G
J Manag Care Spec Pharm; 2019 Sep; 25(9):973-983. PubMed ID: 31313621
[TBL] [Abstract][Full Text] [Related]
14. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
[TBL] [Abstract][Full Text] [Related]
16. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
[No Abstract] [Full Text] [Related]
17. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
18. Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data.
Choong CK; Ford JH; Nyhuis AW; Robinson RL; Aurora SK
J Manag Care Spec Pharm; 2018 Sep; 24(9):921-928. PubMed ID: 30156448
[TBL] [Abstract][Full Text] [Related]
19. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.
Carroll B; Irwin DE
J Manag Care Spec Pharm; 2019 Jul; 25(7):810-816. PubMed ID: 31232207
[TBL] [Abstract][Full Text] [Related]
20. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
Feldman SR; Zhao Y; Shi L; Tran MH
J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
